Vixarelimab

DB16350InvestigationalProtein Based Therapies

Vixarelimab is under investigation in clinical trial NCT03816891 (A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Prurigo Nodularis).

Mechanism: Pharmacologically active on Oncostatin-M-specific receptor subunit beta
Curator reviewed
Also known as: Immunoglobulin g (234-proline,303-glutamine), anti-(human oncostatin m receptor subunit .beta.) (human monoclonal kpl-716 .gamma.-chain), disulfide with human monoclonal kpl-716 .lambda.-chain, dimer
Code names: 30C6 (N73D) IGG4P.AGLY/IGG1 · BIIB-069 · KPL-716 · RO7622888

Resolves to

Compound

UNIIW25GO3A75WCAS2243320-83-2

Targets

Q99650OSMR

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Vixarelimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account